These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 15139748

  • 1. Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?
    Szallasi A, Appendino G.
    J Med Chem; 2004 May 20; 47(11):2717-23. PubMed ID: 15139748
    [No Abstract] [Full Text] [Related]

  • 2. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
    Gomtsyan A, Bayburt EK, Schmidt RG, Zheng GZ, Perner RJ, Didomenico S, Koenig JR, Turner S, Jinkerson T, Drizin I, Hannick SM, Macri BS, McDonald HA, Honore P, Wismer CT, Marsh KC, Wetter J, Stewart KD, Oie T, Jarvis MF, Surowy CS, Faltynek CR, Lee CH.
    J Med Chem; 2005 Feb 10; 48(3):744-52. PubMed ID: 15689158
    [Abstract] [Full Text] [Related]

  • 3. N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.
    Lee J, Lee J, Kang M, Shin M, Kim JM, Kang SU, Lim JO, Choi HK, Suh YG, Park HG, Oh U, Kim HD, Park YH, Ha HJ, Kim YH, Toth A, Wang Y, Tran R, Pearce LV, Lundberg DJ, Blumberg PM.
    J Med Chem; 2003 Jul 03; 46(14):3116-26. PubMed ID: 12825950
    [Abstract] [Full Text] [Related]

  • 4. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology.
    Nagy I, Sántha P, Jancsó G, Urbán L.
    Eur J Pharmacol; 2004 Oct 01; 500(1-3):351-69. PubMed ID: 15464045
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY, Gavva NR.
    Brain Res Rev; 2009 Apr 01; 60(1):267-77. PubMed ID: 19150372
    [Abstract] [Full Text] [Related]

  • 6. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
    Quintanar-Audelo M, Fernández-Carvajal A, Van Den Nest W, Carreño C, Ferrer-Montiel A, Albericio F.
    J Med Chem; 2007 Nov 29; 50(24):6133-43. PubMed ID: 17985859
    [Abstract] [Full Text] [Related]

  • 7. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Tamayo N, Liao H, Stec MM, Wang X, Chakrabarti P, Retz D, Doherty EM, Surapaneni S, Tamir R, Bannon AW, Gavva NR, Norman MH.
    J Med Chem; 2008 May 08; 51(9):2744-57. PubMed ID: 18386885
    [Abstract] [Full Text] [Related]

  • 8. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia.
    Holzer P.
    Eur J Pharmacol; 2004 Oct 01; 500(1-3):231-41. PubMed ID: 15464036
    [Abstract] [Full Text] [Related]

  • 9. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
    Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, Jetter M, Breitenbucher JG, Liu C, Mazur C, Lord B, Gonzales L, Hoey K, Rizzolio M, Bogenstaetter M, Codd EE, Lee DH, Zhang SP, Chaplan SR, Carruthers NI.
    J Med Chem; 2005 Mar 24; 48(6):1857-72. PubMed ID: 15771431
    [Abstract] [Full Text] [Related]

  • 10. Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects.
    Suh YG, Lee YS, Min KH, Park OH, Seung HS, Kim HD, Park HG, Choi J, Lee J, Kang SW, Oh UT, Koo JY, Joo YH, Kim SY, Kim JK, Park YH.
    Bioorg Med Chem Lett; 2003 Dec 15; 13(24):4389-93. PubMed ID: 14643332
    [Abstract] [Full Text] [Related]

  • 11. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ, Chizh BA.
    Drug Discov Today; 2009 Jan 15; 14(1-2):56-67. PubMed ID: 19063991
    [Abstract] [Full Text] [Related]

  • 12. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
    Gavva NR, Bannon AW, Hovland DN, Lehto SG, Klionsky L, Surapaneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang J, Wang W, Zajic G, Zhu D, Norman MH, Louis JC, Magal E, Treanor JJ.
    J Pharmacol Exp Ther; 2007 Oct 15; 323(1):128-37. PubMed ID: 17652633
    [Abstract] [Full Text] [Related]

  • 13. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
    Ognyanov VI, Balan C, Bannon AW, Bo Y, Dominguez C, Fotsch C, Gore VK, Klionsky L, Ma VV, Qian YX, Tamir R, Wang X, Xi N, Xu S, Zhu D, Gavva NR, Treanor JJ, Norman MH.
    J Med Chem; 2006 Jun 15; 49(12):3719-42. PubMed ID: 16759115
    [Abstract] [Full Text] [Related]

  • 14. Capsazepine, a vanilloid receptor antagonist, inhibits allergen-induced tracheal contraction.
    van den Worm E, de Vries A, Nijkamp FP, Engels F.
    Eur J Pharmacol; 2005 Jul 25; 518(1):77-8. PubMed ID: 15996655
    [Abstract] [Full Text] [Related]

  • 15. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
    Knotkova H, Pappagallo M, Szallasi A.
    Clin J Pain; 2008 Feb 25; 24(2):142-54. PubMed ID: 18209521
    [Abstract] [Full Text] [Related]

  • 16. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
    Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, Gomtsyan A, El Kouhen R, Lee CH, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF.
    J Pharmacol Exp Ther; 2005 Jul 25; 314(1):410-21. PubMed ID: 15837818
    [Abstract] [Full Text] [Related]

  • 17. Analysis of structure-activity relationships for the 'B-region' of N-(3-acyloxy-2-benzylpropyl)-N(')-[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: discovery of an N-hydroxythiourea analogue with potent analgesic activity.
    Lee J, Kang SU, Choi HK, Lee J, Lim JO, Kil MJ, Jin MK, Kim KP, Sung JH, Chung SJ, Ha HJ, Kim YH, Pearce LV, Tran R, Lundberg DJ, Wang Y, Toth A, Blumberg PM.
    Bioorg Med Chem Lett; 2004 May 03; 14(9):2291-7. PubMed ID: 15081027
    [Abstract] [Full Text] [Related]

  • 18. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
    Norman MH, Zhu J, Fotsch C, Bo Y, Chen N, Chakrabarti P, Doherty EM, Gavva NR, Nishimura N, Nixey T, Ognyanov VI, Rzasa RM, Stec M, Surapaneni S, Tamir R, Viswanadhan VN, Treanor JJ.
    J Med Chem; 2007 Jul 26; 50(15):3497-514. PubMed ID: 17585749
    [Abstract] [Full Text] [Related]

  • 19. Synthesis of benzamide derivatives as TRPV1 antagonists.
    Shishido Y, Jinno M, Ikeda T, Ito F, Sudo M, Makita N, Ohta A, Iki-Taki A, Ohmi T, Kanai Y, Tamura T, Shimojo M.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1072-8. PubMed ID: 18155908
    [Abstract] [Full Text] [Related]

  • 20. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
    Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, Lee D, Louis JC, Magal E, Manning BH, Rubino J, Surapaneni S, Tamayo N, Wang T, Wang J, Wang J, Wang W, Youngblood B, Zhang M, Zhu D, Norman MH, Gavva NR.
    J Pharmacol Exp Ther; 2008 Jul 01; 326(1):218-29. PubMed ID: 18420600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.